|
| Wednesday, April 5, 2017 |
|
|
Eisai Presents Data of Mechanisms of Action Relating to Tumor Immune Response Regarding Combination of Anticancer Agent Lenvatinib With Anti-PD-1 Antibody at AACR 108th Annual Meeting |
| Eisai Co., Ltd. announced today that it has presented the latest research data regarding a mechanism of action that led to increased anti-tumor activity in mouse models which had been dosed with a combination of the in-house developed anticancer agent lenvatinib mesylate and an anti-mouse PD-1 antibody, at the AACR 108th Annual Meeting. more info >> |
|
| Tuesday, April 4, 2017 |
|
|
Eisai to Launch Smell Identification Test UPSIT Series in Japan |
| Eisai Co., Ltd. has announced that the smell identification test "UPSIT Series" will be launched today for sale to health insurance pharmacies and local governments in Japan. more info >> |
|
| Wednesday, March 29, 2017 |
|
|
Enrollment Commences in Phase III Clinical Study of Eisai's Bace Inhibitor Elenbecestat in Early Alzheimer's Disease in Japan |
| Eisai Co., Ltd. announced today that enrollment has commenced in Japan for MISSION AD1, a global Phase III clinical study of the in-house developed oral beta secretase cleaving enzyme (BACE) inhibitor elenbecestat in patients with early Alzheimer's disease (AD). more info >> |
|
|
German Federal Joint Committee (G-Ba) Confirms Additional Benefit of Anticancer Agent Kisplyx (Lenvatinib Mesylate) in Treatment of Advanced Renal Cell Carcinoma |
| Eisai Co., Ltd. announced today that the German Federal Joint Committee (G-BA) has confirmed the additional benefit of in-house developed anticancer agent Kisplyx (lenvatinib mesylate) in combination with everolimus for the treatment of advanced renal cell carcinoma (RCC) compared to everolimus alone in its assessment for insurance reimbursement. more info >> |
|
| Wednesday, January 25, 2017 |
|
|
Phase III Trial of Anticancer Agent Lenvima as First-Line Treatment for Unresectable Hepatocellular Carcinoma Meets Primary Endpoint |
| Eisai Co., Ltd. announced today that a Phase III clinical trial of its in-house discovered and developed anticancer agent Lenvima against the comparator sorafenib as a first-line treatment for patients with unresectable hepatocellular carcinoma has achieved its primary endpoint. more info >> |
|
| Tuesday, January 24, 2017 |
|
|
Eisai Selected for Excellence in Sustainability Performance and Industry Mover Distinction by Robecosam |
| Eisai Co., Ltd. announced today that it has been selected for excellence in sustainability performance by RobecoSAM AG, a leading assessor of Social Responsibility Investment (SRI). more info >> |
|
| Wednesday, January 18, 2017 |
|
|
Eisai to Participate in Access Accelerated, Global Partnership to Address Rise of Non-Communicable Diseases |
| Eisai Co., Ltd. announced today that it is participating in Access Accelerated, a global partnership to advance access to non-communicable diseases (NCDs) prevention, treatment and care in low and lower-middle income countries. more info >> |
|
| Monday, January 16, 2017 |
|
|
Transfer of Rights to Insomia Treatment / Anaesthesia Induction Agent Flunitrazepam in Japan |
| Eisai Co., Ltd. and Chugai Pharmaceutical Co., Ltd. announced today that Eisai's aquisition of the rights for manufacturing active pharmaceutical ingredients for Japan from F. Hoffman-La Roche Ltd. for the insomnia treatment / anaesthesia induction agent flunitrazepam. more info >> |
|
| Thursday, January 12, 2017 |
|
|
Eisai to Launch Medication Administration Support Device |
| Eisai Co., Ltd. has announced that the medication administration support device e-OKUSURI-SAN will be launched today for sale to pharmacies, medical institutions and caregiving facilities in Japan. more info >> |
|
| Thursday, January 5, 2017 |
|
|
Eisai Acquires All Global Development and Marketing Rights for Chronic Weight Management Treatment Lorcaserin |
| Eisai Co., Ltd. announced today that, in association with its U.S. pharmaceutical subsidiary Eisai Inc., it has reached an agreement with Arena Pharmaceuticals, Inc. to revise the November 2013 marketing and supply agreement it concluded with Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, for the chronic weight management treatment lorcaserin hydrochloride. more info >> |
|
|
|
|
